Results 11 to 20 of about 60,395 (277)

Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes [PDF]

ACS Omega, 2018
Sieun Chae, Dahee Kim, Kyung-jin Lee, Dasol Lee, Young-O Kim, Yong Chae Jung, Sang Dal Rhee, Kwang Rok Kim, Jeong-O Lee, Sunjoo Ahn, Byumseok Koh   +10 more
doaj   +2 more sources

Inhibition of Zn(II) binding type IA topoisomerases by organomercury compounds and Hg(II). [PDF]

PLoS ONE, 2015
Type IA topoisomerase activities are essential for resolving DNA topological barriers via an enzyme-mediated transient single strand DNA break. Accumulation of topoisomerase DNA cleavage product can lead to cell death or genomic rearrangement.
Bokun Cheng, Thirunavukkarasu Annamalai, Shayna Sandhaus, Priyanka Bansod, Yuk-Ching Tse-Dinh   +4 more
doaj   +1 more source

Topoisomerase II as a Novel Antiviral Target against Panarenaviral Diseases

Viruses, 2022
Although many arenaviruses cause severe diseases with high fatality rates each year, treatment options are limited to off-label use of ribavirin, and a Food and Drug Administration (FDA)-approved vaccine is not available.
Tosin Oladipo Afowowe, Yasuteru Sakurai, Shuzo Urata, Vahid Rajabali Zadeh, Jiro Yasuda   +4 more
doaj   +1 more source

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

Nature Communications, 2021
CX-5461 recently progressed through phase I clinical trial as a first-inhuman inhibitor of RNA-POL I. Here, the authors demonstrate that CX-5461 synergizes with topoisomerase I inhibitors to inhibit neuroblastoma cells and that its primary target in this
Min Pan, William C. Wright, Richard H. Chapple, Asif Zubair, Manbir Sandhu, Jake E. Batchelder, Brandt C. Huddle, Jonathan Low, Kaley B. Blankenship, Yingzhe Wang, Brittney Gordon, Payton Archer, Samuel W. Brady, Sivaraman Natarajan, Matthew J. Posgai, John Schuetz, Darcie Miller, Ravi Kalathur, Siquan Chen, Jon Patrick Connelly, M. Madan Babu, Michael A. Dyer, Shondra M. Pruett-Miller, Burgess B. Freeman, Taosheng Chen, Lucy A. Godley, Scott C. Blanchard, Elizabeth Stewart, John Easton, Paul Geeleher   +29 more
doaj   +1 more source

In Vitro Activity of Novel Topoisomerase Inhibitors against Francisella tularensis and Burkholderia pseudomallei

Antibiotics, 2023
Antimicrobial resistance is a global issue, and the investigation of alternative therapies that are not traditional antibiotics are warranted. Novel bacterial type II topoisomerase inhibitors (NBTIs) have recently emerged as a novel class of antibiotics ...
Adam O. Whelan, Ian Cooper, Nicola Ooi, David Orr, Kevin Blades, James Kirkham, Amanda Lyons, Kay B. Barnes, Mark I. Richards, Anne-Marie Salisbury, Mark Craighead, Sarah V. Harding   +11 more
doaj   +1 more source

The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates

Pharmaceutics, 2022
DNA topoisomerases are essential enzymes that stabilize DNA supercoiling and resolve entanglements. Topoisomerase inhibitors have been widely used as anti-cancer drugs for the past 20 years.
Seungmin Han, Kwang Suk Lim, Brody J. Blackburn, Jina Yun, Charles W. Putnam, David A. Bull, Young-Wook Won   +6 more
doaj   +1 more source

Topoisomerase I inhibitors and drug resistance [PDF]

Cytotechnology, 1998
DNA topoisomerase I is a nuclear enzyme which catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. This enzyme represents a novel and distinct molecule target for cancer therapy by antitopoisomerase drugs belonging to the campthotecin series of antineoplastics.
R. E. Parchment, A. Pessina
openaire   +3 more sources

Unraveling topoisomerase IA gate dynamics in presence of PPEF and its preclinical evaluation against multidrug-resistant pathogens

Communications Biology, 2023
Two potent inhibitors PPEF and BPVF of bacterial TopoIA enzymes function by impairing DNA binding and thus DNA cleavage and relaxation activities of bacterial topoisomerase I enzymes.
Vikas Maurya, Raja Singh, Reman Kumar Singh, Stuti Pandey, Pooja Yadav, Palak Parashar, Rajni Gaind, Kshatresh Dutta Dubey, G. Naresh Patwari, Vibha Tandon   +9 more
doaj   +1 more source

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

Thoracic Cancer, 2022
Background Small cell lung cancer (SCLC) is a highly aggressive disease with a poor prognosis. Although most patients initially respond to topoisomerase inhibitors, resistance rapidly emerges.
Miwako Omori, Rintaro Noro, Masahiro Seike, Kuniko Matsuda, Mariko Hirao, Aya Fukuizumi, Natsuki Takano, Akihiko Miyanaga, Akihiko Gemma   +8 more
doaj   +1 more source

Effects of camptothecin derivatives and topoisomerase dual inhibitors on Trypanosoma cruzi growth and ultrastructure [PDF]

, 2014
BACKGROUND: Trypanosoma cruzi is the etiological agent of Chagas’ disease that is an endemic disease in Latin America and affects about 8 million people.
Aline Araujo Zuma, Camila Cristina da Silva, Maria Cristina M Motta, Otto Kischlat Lacombe, Wanderley de Souza   +4 more
core   +1 more source